VistaGen Therapeutics received a U.S. Food and Drug Administration "Study May Proceed" letter on April 22, 2026, authorizing the company to advance the intranasal spray refisolone into Phase 2 clinical development in the United States. The letter confirms that the investigational new drug (IND) application met the FDA’s pre‑clinical and safety requirements, allowing the company to enroll patients and collect efficacy data in the U.S. market.
Refisolone is a non‑hormonal, non‑systemic pherine delivered as an intranasal spray designed to provide rapid relief from menopausal hot flashes. Approximately 75 % of U.S. menopausal women experience hot flashes, creating a sizable unmet need for fast‑acting, non‑hormonal treatments. The product’s nose‑to‑brain delivery platform is intended to achieve quick onset of action while minimizing systemic exposure.
Phase 2a studies conducted in Mexico demonstrated that refisolone reduced hot‑flash frequency by 80 % versus 36 % for placebo, with no serious drug‑related adverse events reported. These results, achieved by Pherin Pharmaceuticals—now a VistaGen subsidiary—provide strong early evidence of efficacy and safety that underpins the FDA’s approval to proceed in the United States.
Shawn Singh, VistaGen’s President and CEO, said the regulatory milestone "marks another important step forward in our women's health program for refisolone. Approximately 75 % of all women in America experience hot flashes during their menopausal transition, yet there is a critical need for new treatment options. As demonstrated in exploratory Phase 2a clinical data, refisolone has the potential to advance women's health and bring a fast‑acting, non‑hormonal treatment option for millions of women seeking relief from menopausal hot flashes." The approval de‑risks the U.S. portion of the program, preserves limited cash resources, and positions VistaGen to pursue a Phase 3 program and eventual regulatory submission.
VistaGen is a small‑cap company with a market capitalization of roughly $23–$24 million. The company recently reduced its workforce by 20 % to manage costs and has been focusing on operational efficiency. The FDA letter represents a key milestone in a company with limited cash, underscoring the strategic importance of advancing refisolone while maintaining financial flexibility.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.